세계의 안내 렌즈 시장 : 유형별, 재료별, 용도별, 최종 사용자별 예측

The intraocular lens market is projected to reach USD 6.17 billion by 2030 from USD 4.62 billion in 2025, at a CAGR of 6.0% during the forecast period.

The intraocular lens market is driven by the rising global prevalence of cataracts, a growing elderly population, and the increasing adoption of premium lenses that offer enhanced visual outcomes. However, high costs of advanced IOLs, reimbursement limitations, and unequal access to skilled ophthalmic care restrain broader uptake. Opportunities emerge from expanding healthcare infrastructure in emerging economies, rising demand for presbyopia-correcting and EDOF IOLs, and continuous innovations aimed at improving postoperative vision and reducing complications, creating strong growth potential across regions.

Based on type, aspheric monofocal IOLs hold the largest market share because they deliver dependable visual clarity, reduce spherical aberrations, and enhance contrast sensitivity at an affordable cost. Their broad surgeon acceptance, strong safety profile, and extensive reimbursement coverage make them the standard choice for routine cataract surgeries. Consistent global availability and proven long-term outcomes further reinforce their dominant market position.

Based on material, hydrophobic acrylic IOLs hold the largest market share due to their excellent biocompatibility, low rates of posterior capsular opacification, and strong long-term optical performance. Surgeons prefer them for their stability, reduced glistening, and high patient satisfaction. Their widespread availability, proven clinical outcomes, and suitability across both standard and premium IOL categories further reinforce their dominant position in the global IOLs market.

North America holds the largest market share in the IOLs market due to its high volume of cataract surgeries, advanced healthcare infrastructure, and strong adoption of premium technologies, such as toric, multifocal, and EDOF IOLs. Favorable reimbursement policies, a well-established network of skilled ophthalmic surgeons, and continuous innovation from leading manufacturers further support market dominance. Additionally, high patient awareness, early uptake of new devices, and substantial healthcare spending reinforce North America's leading position globally.

A breakdown of the primary participants (supply side) for the intraocular lens market referred to in this report is provided below:

• By Company Type: Tier 1 (45%), Tier 2 (30%), and Tier 3 (25%)
• By Designation: C-level Executives (42%), Director-level Executives (29%), and Others (29%)
• By Region: North America (29%), Europe (24%), Asia Pacific (29%), Latin America (10%), Middle East & Africa (5%), and GCC Countries (3%)

Prominent players in the intraocular lens market are Alcon (US), Johnson & Johnson Vision Care, Inc. (US), Carl Zeiss Meditec AG (Germany), HOYA Corporation (Japan), Bausch + Lomb (US), Santen Pharmaceutical Co., Ltd. (Japan), NIDEK CO., LTD. (Japan), Lenstec, Inc. (US), Rayner Group (England), BVI (US), OPHTEC B.V. (Netherlands), SAV-IOL SA (Switzerland), Appasamy Associates Private Limited (India), Atia Vision, Inc. (US), and Biotech (Switzerland), among others.

Research Coverage

The report evaluates the intraocular lens market and estimates the market size and future growth potential of this market based on various segments, including material, type, application, end user, and region. The report also includes a competitive analysis of the major players in this market, along with company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report will assist market leaders and new entrants with data on the nearest approximations of revenue numbers for the overall intraocular lens market and its subsegments. The report will help stakeholders understand the competitive landscape and gain further insights into better positioning their businesses and developing effective go-to-market strategies. The report helps stakeholders understand the market pulse and provides them with data on influential drivers, hindrances, obstacles, and opportunities in the market.

This report provides insights into the following points:

• Analysis of key drivers (increasing geriatric population, rising prevalence of eye disorders, technological advancements in ophthalmic devices, and increased government initiatives to control visual impairment), restraints (high cost of ophthalmology devices, high cost and risk associated with eye surgeries, and the rising adoption of refurbished ophthalmic devices), opportunities (potential growth opportunities in emerging markets and the low adoption of phacoemulsification devices and premium IOLs in emerging markets), and challenges (low accessibility to eye care in low-income countries and lack of skilled professionals)
• Product Enhancement/Innovation: Comprehensive details about product launches and anticipated trends in the global intraocular lens market
• Market Development: Thorough knowledge and analysis of the profitable rising markets by type, material, application, end user, and region
• Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global intraocular lens market
• Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings, and capacities of the major competitors in the global intraocular lens market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: INSIGHTS AND STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING MARKET
• 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 2.5 SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 INTRAOCULAR LENS MARKET OVERVIEW
• 3.2 ASIA PACIFIC: INTRAOCULAR LENS MARKET
• 3.3 INTRAOCULAR LENS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 3.4 INTRAOCULAR LENS MARKET: REGIONAL MIX
• 3.5 INTRAOCULAR LENS MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Increasing geriatric population and subsequent rise in ophthalmic disorders
    • 4.2.1.2 Rising number of cataract surgeries
    • 4.2.1.3 Growing technological advancements in intraocular lens
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 Rising cost of intraocular lenses
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 High growth potential in emerging economies
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Shortage of skilled ophthalmologists
• 4.3 UNMET NEEDS AND WHITE SPACES
  • 4.3.1 UNMET NEEDS IN INTRAOCULAR LENS MARKET
  • 4.3.2 WHITE SPACE OPPORTUNITIES
• 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
  • 4.4.1 INTERCONNECTED MARKETS
  • 4.4.2 CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 BARGAINING POWER OF BUYERS
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 THREAT OF NEW ENTRANTS
  • 5.1.4 THREAT OF SUBSTITUTES
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS AND FORECAST
  • 5.2.3 TRENDS IN GLOBAL OPHTHALMIC EQUIPMENT INDUSTRY
  • 5.2.4 TRENDS IN GLOBAL CATARACT SURGERY INDUSTRY
• 5.3 SUPPLY CHAIN ANALYSIS
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 PRICING ANALYSIS
  • 5.6.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
  • 5.6.2 AVERAGE SELLING PRICE TREND, BY REGION
• 5.7 TRADE ANALYSIS
  • 5.7.1 IMPORT SCENARIO (HS CODE 900290)
  • 5.7.2 EXPORT DATA (HS CODE 900290)
• 5.8 KEY CONFERENCES AND EVENTS, 2025-2027
• 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.10 INVESTMENT AND FUNDING SCENARIO
• 5.11 CASE STUDY ANALYSIS
  • 5.11.1 CASE STUDY 1: ENHANCED REFRACTIVE ACCURACY FOR POST-LASIK CATARACT PATIENTS
  • 5.11.2 CASE STUDY 2: EXPANDING ACCESS TO CATARACT CARE IN LOW-INCOME REGIONS
  • 5.11.3 CASE STUDY 3: DIGITAL WORKFLOW TRANSFORMATION FOR PREMIUM CATARACT SURGERY
• 5.12 IMPACT OF 2025 US TARIFF ON INTRAOCULAR LENS MARKET
  • 5.12.1 INTRODUCTION
  • 5.12.2 KEY TARIFF RATES
  • 5.12.3 PRICE IMPACT ANALYSIS
  • 5.12.4 IMPACT ON COUNTRY/REGION
    • 5.12.4.1 North America
    • 5.12.4.2 Europe
    • 5.12.4.3 Asia Pacific
  • 5.12.5 END-USE INDUSTRY IMPACT

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 KEY EMERGING TECHNOLOGIES
  • 6.1.1 NEXT-GENERATION EDOF AND HYBRID OPTIC DESIGNS
  • 6.1.2 AI-DRIVEN PERSONALIZED IOL PLANNING AND CALCULATION PLATFORMS
• 6.2 COMPLEMENTARY TECHNOLOGIES
  • 6.2.1 ADVANCED BIOMETRY AND DIAGNOSTICS
• 6.3 TECHNOLOGY/PRODUCT ROADMAP
  • 6.3.1 SHORT-TERM (2025-2027) | FOUNDATION & EARLY COMMERCIALIZATION
  • 6.3.2 MID-TERM (2027-2030) | EXPANSION & STANDARDIZATION
  • 6.3.3 LONG-TERM (2030-2035+) | MASS COMMERCIALIZATION & DISRUPTION
• 6.4 PATENT ANALYSIS
  • 6.4.1 JURISDICTION AND TOP APPLICANT ANALYSIS
  • 6.4.2 LIST OF PATENTS
• 6.5 FUTURE APPLICATIONS
  • 6.5.1 POSTOPERATIVE ADJUSTABLE AND CUSTOMIZABLE INTRAOCULAR LENS
  • 6.5.2 REGENERATIVE AND BIOINTEGRATIVE LENS TECHNOLOGIES
  • 6.5.3 AI-INTEGRATED DIGITAL SURGICAL ECOSYSTEMS FOR INTRAOCULAR LENS
• 6.6 IMPACT OF AI/GEN AI ON INTRAOCULAR LENS MARKET
  • 6.6.1 INTRODUCTION
  • 6.6.2 TOP USE CASES AND MARKET POTENTIAL
  • 6.6.3 CASE STUDIES OF AI IMPLEMENTATION IN INTRAOCULAR LENS MARKET
  • 6.6.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
  • 6.6.5 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN INTRAOCULAR LENS MARKET

7 SUSTAINABILITY AND REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS AND COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 INDUSTRY STANDARDS
• 7.2 SUSTAINABILITY INITIATIVES
  • 7.2.1 CARBON IMPACT AND ECO-APPLICATIONS OF INTRAOCULAR LENS
    • 7.2.1.1 Carbon impact reduction
    • 7.2.1.2 Eco-applications
• 7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
• 7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 KEY BUYING CRITERIA
• 8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
• 8.5 MARKET PROFITABILITY
  • 8.5.1 REVENUE POTENTIAL
  • 8.5.2 COST DYNAMICS
  • 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS

9 INTRAOCULAR LENS MARKET, BY TYPE

• 9.1 INTRODUCTION
• 9.2 MONOFOCAL INTRAOCULAR LENSES
  • 9.2.1 ASPHERIC MONOFOCAL INTRAOCULAR LENSES
    • 9.2.1.1 Increased visual quality and performance to propel market
  • 9.2.2 SPHERIC MONOFOCAL INTRAOCULAR LENSES
    • 9.2.2.1 Cost-effectiveness to drive market
• 9.3 PREMIUM INTRAOCULAR LENSES
  • 9.3.1 MULTIFOCAL INTRAOCULAR LENSES
    • 9.3.1.1 Enhanced visual acuity to support growth
  • 9.3.2 EXTENDED DEPTH OF FOCUS (EDOF) INTRAOCULAR LENSES
    • 9.3.2.1 Broader range of clear vision to drive market
  • 9.3.3 ACCOMMODATING INTRAOCULAR LENSES
    • 9.3.3.1 High utilization in cataract correction to aid growth
• 9.4 PHAKIC INTRAOCULAR LENSES
  • 9.4.1 LIMITED AWARENESS AND COST CONCERNS TO RESTRAIN MARKET
• 9.5 OTHER INTRAOCULAR LENSES

10 INTRAOCULAR LENS MARKET, BY MATERIAL

• 10.1 INTRODUCTION
• 10.2 HYDROPHOBIC ACRYLIC IOL
  • 10.2.1 INCREASED BIOCOMPATIBILITY AND HEIGHTENED STABILITY TO DRIVE MARKET
• 10.3 HYDROPHILIC ACRYLIC IOL
  • 10.3.1 GLARE REDUCTION AND INCREASED COMPRESSIBILITY TO PROPEL MARKET
• 10.4 POLYMETHYLMETHACRYLATE
  • 10.4.1 LOW MATERIAL COST AND ADVANCED DURABILITY TO BOOST MARKET
• 10.5 SILICONE IOL
  • 10.5.1 LOW AWARENESS AND LIMITED FOLDABILITY TO RESTRAIN MARKET
• 10.6 OTHER MATERIALS

11 INTRAOCULAR LENS MARKET, BY APPLICATION

• 11.1 INTRODUCTION
• 11.2 CATARACT SURGERIES
  • 11.2.1 RISING GERIATRIC POPULATION TO FACILITATE GROWTH
• 11.3 PRESBYOPIA
  • 11.3.1 GROWING AWARENESS OF TECHNOLOGICALLY ADVANCED LENSES TO BOOST MARKET
• 11.4 CORNEAL DISORDERS
  • 11.4.1 INCREASING PREFERENCE FOR MINIMALLY INVASIVE SURGERIES TO SPUR GROWTH
• 11.5 OTHER APPLICATIONS

12 INTRAOCULAR LENS MARKET, BY END USER

• 12.1 INTRODUCTION
• 12.2 HOSPITALS
  • 12.2.1 HIGH PURCHASING POWER FOR ADVANCED EQUIPMENT TO PROPEL MARKET
• 12.3 OPHTHALMOLOGY CLINICS
  • 12.3.1 REDUCED WAITING TIME AND MINIMAL COST OF DIAGNOSTIC & SURGICAL PROCEDURES TO DRIVE MARKET
• 12.4 EYE RESEARCH INSTITUTES
  • 12.4.1 INCREASING R&D ON INTRAOCULAR LENS TECHNOLOGIES TO ENCOURAGE GROWTH
• 12.5 OTHER END USERS

13 INTRAOCULAR LENS MARKET, BY REGION

• 13.1 INTRODUCTION
• 13.2 NORTH AMERICA
  • 13.2.1 US
    • 13.2.1.1 Favorable reimbursement policies to drive market
  • 13.2.2 CANADA
    • 13.2.2.1 Large target population to fuel market
• 13.3 EUROPE
  • 13.3.1 GERMANY
    • 13.3.1.1 Increasing public healthcare expenditure to aid growth
  • 13.3.2 FRANCE
    • 13.3.2.1 Government initiatives for visual care awareness to support growth
  • 13.3.3 UK
    • 13.3.3.1 Growing healthcare expenditure to facilitate growth
  • 13.3.4 ITALY
    • 13.3.4.1 Increasing R&D initiatives for eye care to spur growth
  • 13.3.5 SPAIN
    • 13.3.5.1 Rising healthcare spending to encourage growth
  • 13.3.6 REST OF EUROPE
• 13.4 ASIA PACIFIC
  • 13.4.1 JAPAN
    • 13.4.1.1 Rising geriatric population to boost demand
  • 13.4.2 CHINA
    • 13.4.2.1 Improved healthcare infrastructure to support growth
  • 13.4.3 INDIA
    • 13.4.3.1 Rising number of cataract surgeries to drive market
  • 13.4.4 AUSTRALIA
    • 13.4.4.1 High focus on R&D for advanced IOLs to fuel market
  • 13.4.5 SOUTH KOREA
    • 13.4.5.1 Rising adoption of technologically advanced intraocular lenses to boost market
  • 13.4.6 REST OF ASIA PACIFIC
• 13.5 LATIN AMERICA
  • 13.5.1 BRAZIL
    • 13.5.1.1 Government initiatives for healthcare infrastructure to boost market
  • 13.5.2 MEXICO
    • 13.5.2.1 Rising incidence of chronic diseases to support growth
  • 13.5.3 REST OF LATIN AMERICA
• 13.6 MIDDLE EAST & AFRICA
  • 13.6.1 EXPANDING ACCESS TO VISION CARE TO ACCELERATE GROWTH
• 13.7 GCC COUNTRIES
  • 13.7.1 RISE IN CAMPAIGNS TO BOOST AWARENESS FOR CATARACT SURGERIES AND TREATMENT TO DRIVE MARKET

14 COMPETITIVE LANDSCAPE

• 14.1 OVERVIEW
• 14.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN
• 14.3 REVENUE ANALYSIS, 2020-2024
• 14.4 MARKET SHARE ANALYSIS, 2024
• 14.5 US MARKET SHARE ANALYSIS
• 14.6 BRAND/PRODUCT COMPARISON
• 14.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 14.7.1 STARS
  • 14.7.2 EMERGING LEADERS
  • 14.7.3 PERVASIVE PLAYERS
  • 14.7.4 PARTICIPANTS
  • 14.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 14.7.5.1 Company footprint
    • 14.7.5.2 Region footprint
    • 14.7.5.3 Type footprint
    • 14.7.5.4 Material footprint
    • 14.7.5.5 Application footprint
    • 14.7.5.6 End-user footprint
• 14.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 14.8.1 PROGRESSIVE COMPANIES
  • 14.8.2 RESPONSIVE COMPANIES
  • 14.8.3 DYNAMIC COMPANIES
  • 14.8.4 STARTING BLOCKS
  • 14.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 14.8.5.1 Detailed list of key startups/SMEs
    • 14.8.5.2 Competitive benchmarking of key startups/SMEs
• 14.9 COMPANY VALUATION AND FINANCIAL METRICS
  • 14.9.1 COMPANY VALUATION
  • 14.9.2 FINANCIAL METRICS
• 14.10 COMPETITIVE SCENARIO
  • 14.10.1 PRODUCT LAUNCHES AND APPROVALS
  • 14.10.2 DEALS
  • 14.10.3 EXPANSIONS

15 COMPANY PROFILES

• 15.1 KEY PLAYERS
  • 15.1.1 ALCON
    • 15.1.1.1 Business overview
    • 15.1.1.2 Products offered
    • 15.1.1.3 Recent developments
      • 15.1.1.3.1 Product launches and approvals
      • 15.1.1.3.2 Deals
    • 15.1.1.4 MnM view
      • 15.1.1.4.1 Key strengths/Right to win
      • 15.1.1.4.2 Strategic choices
      • 15.1.1.4.3 Weaknesses/Competitive threats
  • 15.1.2 JOHNSON & JOHNSON VISION CARE, INC.
    • 15.1.2.1 Business overview
    • 15.1.2.2 Products offered
    • 15.1.2.3 Recent developments
      • 15.1.2.3.1 Product launches and approvals
    • 15.1.2.4 MnM view
      • 15.1.2.4.1 Key strengths/Right to win
      • 15.1.2.4.2 Strategic choices
      • 15.1.2.4.3 Weaknesses/Competitive threats
  • 15.1.3 BAUSCH + LOMB
    • 15.1.3.1 Business overview
    • 15.1.3.2 Products offered
    • 15.1.3.3 Recent developments
      • 15.1.3.3.1 Product launches and approvals
      • 15.1.3.3.2 Deals
    • 15.1.3.4 MnM view
      • 15.1.3.4.1 Key strengths/Right to win
      • 15.1.3.4.2 Strategic choices
      • 15.1.3.4.3 Weaknesses/Competitive threats
  • 15.1.4 CARL ZEISS MEDITEC AG
    • 15.1.4.1 Business overview
    • 15.1.4.2 Products offered
    • 15.1.4.3 Recent developments
      • 15.1.4.3.1 Product launches and approvals
      • 15.1.4.3.2 Deals
    • 15.1.4.4 MnM view
      • 15.1.4.4.1 Key strengths/Right to win
      • 15.1.4.4.2 Strategic choices
      • 15.1.4.4.3 Weaknesses/Competitive threats
  • 15.1.5 HOYA CORPORATION
    • 15.1.5.1 Business overview
    • 15.1.5.2 Products offered
    • 15.1.5.3 Recent developments
      • 15.1.5.3.1 Deals
    • 15.1.5.4 MnM view
      • 15.1.5.4.1 Key strengths/Right to win
      • 15.1.5.4.2 Strategic choices
      • 15.1.5.4.3 Weaknesses/Competitive threats
  • 15.1.6 SANTEN PHARMACEUTICAL CO., LTD.
    • 15.1.6.1 Business overview
    • 15.1.6.2 Products offered
  • 15.1.7 NIDEK CO., LTD.
    • 15.1.7.1 Business overview
    • 15.1.7.2 Products offered
    • 15.1.7.3 Recent developments
      • 15.1.7.3.1 Deals
  • 15.1.8 LENSTEC, INC.
    • 15.1.8.1 Business overview
    • 15.1.8.2 Products offered
    • 15.1.8.3 Recent developments
      • 15.1.8.3.1 Other developments
  • 15.1.9 RAYNER GROUP
    • 15.1.9.1 Business overview
    • 15.1.9.2 Products offered
    • 15.1.9.3 Recent developments
      • 15.1.9.3.1 Product launches and approvals
  • 15.1.10 BVI
    • 15.1.10.1 Business overview
    • 15.1.10.2 Products offered
    • 15.1.10.3 Recent developments
      • 15.1.10.3.1 Product launches and approvals
      • 15.1.10.3.2 Expansions
  • 15.1.11 OPHTEC B.V.
    • 15.1.11.1 Business overview
    • 15.1.11.2 Products offered
  • 15.1.12 SAV-IOL SA
    • 15.1.12.1 Business overview
    • 15.1.12.2 Products offered
  • 15.1.13 APPASAMY ASSOCIATES PRIVATE LIMITED
    • 15.1.13.1 Business overview
    • 15.1.13.2 Products offered
  • 15.1.14 ATIA VISION, INC.
    • 15.1.14.1 Business overview
    • 15.1.14.2 Products offered
  • 15.1.15 ADAPTILENS
    • 15.1.15.1 Business overview
    • 15.1.15.2 Products offered
• 15.2 OTHER PLAYERS
  • 15.2.1 BIOTECH
  • 15.2.2 TELEON SURGICAL BV
  • 15.2.3 OMNI LENS PVT. LTD.
  • 15.2.4 EYEKON MEDICAL
  • 15.2.5 HUMANOPTICS HOLDING AG
  • 15.2.6 CARE GROUP
  • 15.2.7 SIFI S.P.A.
  • 15.2.8 HANITA LENSES LTD.
  • 15.2.9 EXCELLENT HI-CARE PVT LTD.
  • 15.2.10 ADVIN HEALTH CARE

16 RESEARCH METHODOLOGY

• 16.1 RESEARCH DATA
  • 16.1.1 SECONDARY DATA
    • 16.1.1.1 Key data from secondary sources
  • 16.1.2 PRIMARY DATA
    • 16.1.2.1 Key data from primary sources
    • 16.1.2.2 Key primary participants
    • 16.1.2.3 Breakdown of primary interviews
    • 16.1.2.4 Key industry insights
• 16.2 MARKET SIZE ESTIMATION
• 16.3 DATA TRIANGULATION
• 16.4 MARKET SHARE ESTIMATION
• 16.5 RESEARCH ASSUMPTIONS
• 16.6 RESEARCH LIMITATIONS AND RISK ASSESSMENT
  • 16.6.1 RESEARCH LIMITATIONS
  • 16.6.2 RISK ASSESSMENT

17 APPENDIX

• 17.1 DISCUSSION GUIDE
• 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 17.3 CUSTOMIZATION OPTIONS
• 17.4 RELATED REPORTS
• 17.5 AUTHOR DETAILS